Want to see ATOS full AI Analyst Report?
ATOS Stock Chart & Stats
$5.83
>-$0.01(-0.49%)
At close: 4:00 PM EST
$5.83
>-$0.01(-0.49%)
Day’s Range― - ―
52-Week Range$1.70 - $19.33
Previous CloseN/A
Volume314.80K
Average Volume (3M)1.16M
Market Cap
$23.54M
Enterprise Value-$14.62M
Total Cash (Recent Filing)$31.72M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Aug 17, 2026EPS Estimate
-1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.37
Shares Outstanding9,974,998
10 Day Avg. Volume1,949,046
30 Day Avg. Volume1,157,820
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.94
Price to Sales (P/S)0.00
P/FCF Ratio-2.56
Enterprise Value/Market Cap-0.62
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.83K
Enterprise Value/Ebitda0.39
Forecast
1Y Price Target
$16.00Price Target Upside174.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.33
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / No DebtHaving no recorded debt is a durable structural strength: it lowers fixed financial obligations, preserves flexibility to prioritize R&D spending, and reduces insolvency risk. For a clinical-stage biotech, low leverage improves optionality for future financing and partnership negotiations.
Resolved IP Disputes For EndoxifenThe patent settlement meaningfully reduces legal overhang and clarifies freedom-to-operate for Z-endoxifen development. That structural reduction in IP uncertainty strengthens competitive positioning, supports clearer clinical and licensing strategies, and lowers the risk premium for multi-month program planning.
Governance And Capital Structure FlexibilityShareholder approvals signal governance continuity and give management tactical tools (e.g., reverse split authorization) to manage listing and capital-raising mechanics. This durable governance backing and procedural flexibility improve the company's ability to execute financings and maintain listing compliance.
Bears Say
No Revenue And Widening LossesA clinical-stage model without revenue leaves the company fully dependent on external funding. Widening net losses indicate rising expense intensity relative to progress, reducing runway and increasing financing frequency. Over months this limits strategic autonomy and heightens dilution risk.
Accelerating Cash Burn / Negative FCFConsistently negative and accelerating free cash flow is a persistent structural weakness: it necessitates recurrent capital raises to fund trials and operations. Growing burn increases dilution risk, shortens actionable runway, and can force trade-offs between programs or slow clinical timelines.
Declining Shareholders' Equity And AssetsA shrinking equity base reflects sustained losses and asset depletion, weakening the company's balance-sheet cushion. Over time this reduces capacity to absorb setbacks, limits borrowing or partnership leverage, and raises the likelihood that future financing will be more dilutive or restrictive.
Atossa Therapeutics News
ATOS FAQ
What was Atossa Therapeutics’s price range in the past 12 months?
Atossa Therapeutics lowest stock price was $1.70 and its highest was $19.33 in the past 12 months.
What is Atossa Therapeutics’s market cap?
Atossa Therapeutics’s market cap is $23.54M.
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is Aug 17, 2026 which is in 37 days.
How were Atossa Therapeutics’s earnings last quarter?
Atossa Therapeutics released its earnings results on May 08, 2026. The company reported -$1.11 earnings per share for the quarter, missing the consensus estimate of -$0.99 by -$0.12.
Is Atossa Therapeutics overvalued?
According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
Does Atossa Therapeutics pay dividends?
Atossa Therapeutics does not currently pay dividends.
What is Atossa Therapeutics’s EPS estimate?
Atossa Therapeutics’s EPS estimate is -1.05.
How many shares outstanding does Atossa Therapeutics have?
Atossa Therapeutics has 9,974,998 shares outstanding.
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Atossa Therapeutics reported an EPS of -$1.11 in its last earnings report, missing expectations of -$0.99. Following the earnings report the stock price went down -1.235%.
Which hedge fund is a major shareholder of Atossa Therapeutics?
Currently, no hedge funds are holding shares in ATOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
ATOS Stock 12 Month Forecast
Average Price Target
$16.00
▲(174.44% Upside)
Technical Analysis
Ownership Overview
2.17% Insiders
27.43% Mutual Funds
<0.01% Other Institutional Investors
66.52% Public Companies and
Individual Investors